Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7358822 | 0.74 | GAA (0.39) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL14984829 | 0.71 | ALDH1A1 (0.44) | ALDH1A1MAPTRECQLSMN1; SMN2HIF1A | |
| SCHEMBL4417899 | 0.71 | KDM4E (0.44) | ALDH1A1KDM4EKMT2AMEN1USP2 | |
| SCHEMBL644646 | 0.71 | TSHR (0.45) | ALDH1A1HDAC8GAATDP1STING1 | |
| SCHEMBL7358239 | 0.70 | HPGD (0.51) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL11327841 | 0.70 | HPGD (0.58) | ALDH1A1KMT2AMAPTMEN1POLB | |
| SCHEMBL10982252 | 0.69 | CYP4F2 (0.50) | ALDH1A1KMT2ATDP1 | |
| SCHEMBL31124644 | 0.69 | LMNA (0.47) | ALDH1A1KDM4EHDAC8KMT2AMEN1 | |
| SCHEMBL13643874 | 0.69 | HPGD (0.38) | ALDH1A1KMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL2633151 | 0.69 | KMT2A (0.50) | ALDH1A1KDM4EKMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428370-B2 | Haloallylamine dual amine oxidase inhibitors | SYNTARA LIMITED (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20230257342-A1 | HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS | PHARMAXIS LTD. (AU) | 2023-08-17 | — | — | US | disclosed |
| US-20230257342-A1 | HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS | PHARMAXIS LTD. (AU) | 2023-08-17 | — | — | US | disclosed |
| US-20230257342-A1 | HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS | PHARMAXIS LTD. (AU) | 2023-08-17 | — | — | US | disclosed |
| EP-4171740-A1 | HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS | Pharmaxis Ltd. (AU) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021258159-A1 | HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS | PHARMAXIS LTD. (AU) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257342-A1 | HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS | AOC2, AOC3, AOC1 | ALDH1A1 52/4885KDM4E 2191/4885HDAC8 2513/4885 |
| US-12428370-B2 | Haloallylamine dual amine oxidase inhibitors | AOC2, AOC3, AOC1 | ALDH1A1 52/4885KDM4E 2191/4885HDAC8 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.